The phenotypes of chronic heart failure in patients with ischemic heart disease combined with chronic obstructive pulmonary disease.

The aim of this study: on the basis of clinical and instrumental complex investigation of 320 patients with chronic heart failure (CHF) of ischemic etiology combined with chronic obstructive pulmonary disease (COPD) it was proposed to identify several phenotypes of including CHF with preserved ejection fraction (CHFpEF) without right ventricular dysfunction (RVD); CHFpEF with RVD; CHFpEF with right-side failure (RSF); CHF with reduced EF (CHFrEF) plus RSF (biventricular). Identification of these phenotypes creates the pathophysiologic basis to development of rathional pharmacotherapy of CHF in patients with ischemic heart disease combined with COPD

The phenotypes of chronic heart failure in patients with ischemic heart disease combined with chronic obstructive pulmonary disease.

The aim of this study: on the basis of clinical and instrumental complex investigation of 320 patients with chronic heart failure (CHF) of ischemic etiology combined with chronic obstructive pulmonary disease (COPD) it was proposed to identify several phenotypes of including CHF with preserved ejection fraction (CHFpEF) without right ventricular dysfunction (RVD); CHFpEF with RVD; CHFpEF with right-side failure (RSF); CHF with reduced EF (CHFrEF) plus RSF (biventricular). Identification of these phenotypes creates the pathophysiologic basis to development of rathional pharmacotherapy of CHF in patients with ischemic heart disease combined with COPD

Daily profile and variability of blood pressure in patients with arterial hypertension (AH) in combination with COPD.

To date, despite the improved approach to managing patients with AH, control of blood pressure remains unsatisfactory in some categories of patients. This problem is particularly topical in AH combined with COPD depending on the peculiarities of the course and difficulty in their diagnosis. Thanks  to the use of 24-hour monitoring method, it is possible to objectify the true blood pressure profile during the day and diagnose AH at a qualitatively new level. In patients with a combination of AH and COPD, there are certain features of the clinical course that can be determined with the use of 24-hour BP monitoring. A direct relationship between the profile of blood pressure, the clinical groups of COPD, as well as the time of its onset regarding hypertension was revealed

Adherence to treatment of patients with past ischemic stroke.

The main task of the general practitioner is managing patients with the effects of ischemic stroke. The improvement of patients adherence to treatment in a significant way contributes to successful secondary prevention of ischemic stroke. Adherence to treatment can be determined through various questionnaires, including Morissky-Green. Currently, the adherence to a long-term drug therapy remains insufficient

Cognitive impairments in patients with heart failure of ischemic genesis.

Heart failure is a complex clinical syndrome with multiple interactions between the myocardium and the brain. These bidirectional interactions are characterized by pathophysiological features that determine the clinical picture, including the presence of cognitive impairment. The study showed that the degree of cognitive impairment depends on the severity of heart failure and correlates with the magnitude of the left ventricular ejection fraction

The role of out-of-class work of doctor-interns in improving qualitive academic progress on clinical immunology and allergology under the primary specialization “Internal diseases”.

The use of independent out-of-class work of interns on the specialty "Internal diseases" in the section of clinical immunology and allergology promoted the improvement of the qualitative success of interns

Primary prevention efforts are poorly developed in people at high cardiovascular risk: A report from the European Society of Cardiology EURObservational Research Programme EUROASPIRE V survey in 16 European countries

Background: European Action on Secondary and Primary Prevention by Intervention to Reduce Events (EUROASPIRE) V in primary care was carried out by the European Society of Cardiology EURObservational Research Programme in 2016–2018. The main objective was to determine whether the 2016 Joint European Societies’ guidelines on cardiovascular disease prevention in people at high cardiovascular risk have been implemented in clinical practice. Methods: The method used was a cross-sectional survey in 78 centres from 16 European countries. Patients without a history of atherosclerotic cardiovascular disease either started on blood pressure and/or lipid and/or glucose lowering treatments were identified and interviewed 6 months after the start of medication. Results: A total of 3562 medical records were reviewed and 2759 patients (57.6% women; mean age 59.0 11.6 years) interviewed (interview rate 70.0%). The risk factor control was poor with 18.1% of patients being smokers, 43.5% obese (body mass index 30 kg/m2 ) and 63.8% centrally obese (waist circumference 88 cm for women, 102 cm for men). Of patients on blood pressure lowering medication 47.0% reached the target of <140/90 mm Hg (<140/85 mm Hg in people with diabetes). Among treated dyslipidaemic patients only 46.9% attained low density lipoprotein-cholesterol target of <2.6 mmol/l. Among people treated for type 2 diabetes mellitus, 65.2% achieved the HbA1c target of <7.0%. Conclusion: The primary care arm of the EUROASPIRE V survey revealed that large proportions of people at high cardiovascular disease risk have unhealthy lifestyles and inadequate control of blood pressure, lipids and diabetes. Thus, the potential to reduce the risk of future cardiovascular disease throughout Europe by improved preventive cardiology programmes is substantial

The Phenotypes of Chronic Heart Failure in Patients with Ischemic Heart Disease Combined with Chronic Obstructive Pulmonary Disease.

The aim of this study: on the basis of clinical and instrumental complex investigation of 320 patients with chronic heart failure (CHF) of ischemic etiology combined with chronic obstructive pulmonary disease (COPD) it was proposed to identify several phenotypes of including CHF with preserved ejection fraction (CHFpEF) without right ventricular dysfunction (RVD); CHFpEF with RVD; CHFpEF with right-side failure (RSF); CHF with reduced EF (CHFrEF) plus RSF (biventricular). Identification of these phenotypes creates the pathophysiologic basis to development of rathional pharmacotherapy of CHF in patients with ischemic heart disease combined with COPD